Immunoprecise Antibodies Ltd (IPA)
$1.77
$-0.30
(-14.49%)
As on 02-Oct-2025 09:30EDT
Market cap
$96 Mln
Revenue (TTM)
$25 Mln
P/E Ratio
--
P/B Ratio
5.6
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-4.7
-
Debt to Equity
0.6
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
46,154,100
10 Years Aggregate
CFO
CA$-38.89 Mln
EBITDA
CA$-47.34 Mln
Net Profit
CA$-73.57 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Immunoprecise Antibodies (IPA)
| 329.9 | -25.3 | 62.4 | 202.8 | -23.7 | -29.3 | -- |
|
BSE Sensex*
| -11.1 | -2.1 | -8.9 | -7.5 | 6.6 | 9.1 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|
|
Immunoprecise Antibodies (IPA)
| -67.2 | -2.8 | -64.1 | 3,295.4 | -13.8 | 9.4 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Immunoprecise Antibodies (IPA)
|
1.8 | 95.5 | 24.5 | -30.2 | -138.5 | -105.1 | -- | 5.6 |
| 1.3 | 149.1 | 0.0 | -33.8 | -- | -158.8 | -- | 11.3 | |
| 0.2 | 1.6 | 54.7 | -11.3 | -16.3 | -516.3 | -- | 0.9 | |
| 1.1 | 184.2 | 279.9 | 18.2 | -4.3 | 4.8 | 11.9 | 0.7 | |
| 1.4 | 372.2 | 937.4 | -11.0 | -0.7 | -1 | -- | 0.5 |
Shareholding Pattern
View DetailsAbout Immunoprecise Antibodies (IPA)
ImmunoPrecise Antibodies Ltd. operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company. It discovers and develops customized and novel antibodies by generating proprietary and patented processes,... procedures, and innovative approaches to antibody discovery, development, and production. The company was incorporated in 1983 and is headquartered in Austin, Texas. Read more
-
CEO, President & Non-Independent Director
Dr. Jennifer Lynne Bath Ph.D.
-
CEO, President & Non-Independent Director
Dr. Jennifer Lynne Bath Ph.D.
-
Headquarters
Austin, TX
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Immunoprecise Antibodies (IPA)
What is the current share price of Immunoprecise Antibodies Ltd (IPA) Today?
The share price of Immunoprecise Antibodies Ltd (IPA) is $1.77 (NASDAQ) as of 02-Oct-2025 09:30 EDT. Immunoprecise Antibodies Ltd (IPA) has given a return of -23.73% in the last 3 years.
What is the current PB & PE ratio of Immunoprecise Antibodies Ltd (IPA)?
Since, TTM earnings of Immunoprecise Antibodies Ltd (IPA) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
What is the 52 Week High and Low of Immunoprecise Antibodies Ltd (IPA)?
The 52-week high and low of Immunoprecise Antibodies Ltd (IPA) are Rs 3.25 and Rs 0.27 as of 15-May-2026.
What is the market cap of Immunoprecise Antibodies Ltd (IPA)?
Immunoprecise Antibodies Ltd (IPA) has a market capitalisation of $ 96 Mln as on 02-Oct-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in Immunoprecise Antibodies Ltd (IPA)?
Before investing in Immunoprecise Antibodies Ltd (IPA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.